NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma

[1]  G. Gores,et al.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management , 2020, Nature Reviews Gastroenterology & Hepatology.

[2]  M. Borad,et al.  Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[3]  G. Gores,et al.  Cholangiocarcinoma — evolving concepts and therapeutic strategies , 2018, Nature Reviews Clinical Oncology.

[4]  M. Ando,et al.  Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer , 2018, The British journal of surgery.

[5]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[6]  M. Miyazaki,et al.  Intrahepatic cholangiocarcinoma: expert consensus statement. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[7]  Y Quijano,et al.  Stromal disrupting effects of nab-paclitaxel in pancreatic cancer , 2013, British Journal of Cancer.

[8]  W. Jarnagin,et al.  Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. , 2001, Journal of the American College of Surgeons.

[9]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[10]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.